Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of developing a cross-departmental strategy including the (a) Department for Science, Innovation and Technology and (b) NHS to (i) support and (ii) promote expertise in cell and gene therapy innovation.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department recognises that advanced cell and gene therapies will be an important part of the future of healthcare and the life sciences industry. The Department has been considering the recommendations of the National Cell and Gene Therapy Vision for the UK, a report published by the Cell and Gene Therapy Catapult in March 2022, and the UK Strategic Stem Cell Forum’s latest report, A 10 Year Vision for Stem Cell Transplantation and Advanced Cellular Therapies, published in July 2022. As part of this we have been conducting stakeholder engagement across the cell and gene therapy ecosystem to further understand the challenges raised and whether there is a role for the Department in coordinating activity in this area. We will continue to work with our public sector partners to ensure a whole system approach to advanced therapies, building on existing strengths to ensure a joined-up research, regulatory, and health ecosystem.
Asked by: Jackie Doyle-Price (Conservative - Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of increasing self-sufficiency in UK stem cell donations.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The UK Stem Cell Strategic Forum, a Departmental advisory body, has recommended in its report A 10 Year Vision for Stem Cell Transplantation and Advanced Cellular Therapies that donor to patient unrelated donations in the United Kingdom should be increased to 45%. This will improve the sustainability and resilience of UK stem cell supply, maintain the UK’s expertise in stem cell provision and support adoption of advanced cellular therapies. The Department is investing £2.4 million between April 2022 and March 2025 to recruit stem cell donors to improve resilience and help address health inequalities.
Asked by: Jackie Doyle-Price (Conservative - Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will review the (a) terms of reference and (b) governance of the UK Stem Cell strategic forum.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The terms of reference and governance of the UK Stem Cell Strategic Forum are reviewed periodically and on an ad hoc basis as required. The Forum published its latest report A 10 Year Vision for Stem Cell Transplantation and Advanced Cellular Therapies in July 2022 to address weaknesses in stem cell transplantation services. The Forum is working with the Department, NHS England, NHS Blood and Transplant, clinicians, industry, and representatives of patient groups to take the recommendations forward. An oversight committee and five working groups have been established in line with the current terms of reference.
Jan. 10 2012
Source Page: Taking stock of regenerative medicine in the United Kingdom. 58 p.Found: , developmental and stem cell biology, gene therapy, cellular therapeutics and new biomaterials (scaffolds
Mentions:
1: Mark Tami (LAB - Alyn and Deeside) am chair of the all-party group on stem cell transplantation and advanced cellular therapies.Many Members - Speech Link
2: Mark Tami (LAB - Alyn and Deeside) cell transplantation on patients and families. - Speech Link
3: Neil O'Brien (CON - Harborough) As chair of the all-party parliamentary group on stem cell transplantation and advanced cellular therapies - Speech Link
Asked by: Henry Smith (Conservative - Crawley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential support for UK leadership in the adoption of cell and gene therapies of the recommendations of the Cell and Gene Therapy Catapult’s National Cell and Gene Therapy Vision for the UK, published in March 2022.
Answered by Will Quince
The Department recognises that advanced cell and gene therapies will be an important part of the future of healthcare and the life sciences industry. We have been considering the recommendations of the Cell and Gene Therapy Catapult’s ‘National Cell and Gene Therapy Vision for the UK’, a report published by the Cell and Gene Therapy Catapult in March 2022 and the UK Strategic Stem Cell Forum’s latest report ‘A 10-year vision for stem cell transplantation and cellular therapies’ published in July 2022.
As part of this, we have been conducting stakeholder engagement to further understand the challenges raised and whether there is a role for the Department in coordinating activity in this area.
Dec. 10 2008
Source Page: Gene Therapy Advisory Committee: 14th Annual Report. 84 p.Found: cell science into real therapies for all our patients.
Apr. 12 2024
Source Page: Non-technical summaries granted in 2024Found: stem cell therapies for neurodegenerative and neovascular conditions in the eye and brain, and there
Written Evidence Jun. 28 2023
Inquiry: Future cancerFound: Treatment Treatment focus in the coming years should focus on cellular therapies, (CAR-T), increasing
Nov. 28 2023
Source Page: Clinical Impact Awards 2022: personal statementsFound: cell, CAR- T & cord blood trials & nationally commissioned stem cell & gene therapies. 3) As trust